Of course, this is largely moot in patients with T2D and CVD, such as those participating in these trials, where their very high CV risk already mandates an aggressive approach to risk reduction, including consideration of SGLT2 inhibitors, potentially as first-line agents. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.